2. Metabolic Enzyme/Protease Anti-infection Immunology/Inflammation JAK/STAT Signaling Stem Cell/Wnt
  3. Glutathione S-transferase Influenza Virus Interleukin Related IFNAR STAT
  4. Cappariloside A

Cappariloside A is a larvicide that exhibits larvicidal activity against Aedes aegypti larvae and reduces larval glutathione-S-transferase activity. Cappariloside A also possesses antiviral activity, decreases the level of phosphorylated STAT1 in cells, inhibits the replication of influenza viruses H1N1, H3N2, PIV3 and ADV, and downregulates the expression of IL-6, IP-10, MIG, RANTES/CCL-5, IFN-β and IL-29. Cappariloside A suppresses the inflammatory response induced by mouse lung-adapted influenza virus strains. Cappariloside A can be used in studies related to larvicidal applications and influenza virus infection.

For research use only. We do not sell to patients.

Cappariloside A

Cappariloside A Chemical Structure

CAS No. : 229483-41-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Cappariloside A Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cappariloside A is a larvicide that exhibits larvicidal activity against Aedes aegypti larvae and reduces larval glutathione-S-transferase activity. Cappariloside A also possesses antiviral activity, decreases the level of phosphorylated STAT1 in cells, inhibits the replication of influenza viruses H1N1, H3N2, PIV3 and ADV, and downregulates the expression of IL-6, IP-10, MIG, RANTES/CCL-5, IFN-β and IL-29. Cappariloside A suppresses the inflammatory response induced by mouse lung-adapted influenza virus strains. Cappariloside A can be used in studies related to larvicidal applications and influenza virus infection[1][2].

In Vitro

Cappariloside A (Compound 1) (24-48 h) exhibits larvicidal activity against 3rd-instar *Aedes aegypti* larvae, with an LC50 value of 71.14 ppm[1].
Cappariloside A (71.14 ppm; 24 h) reduces the activity of glutathione-S-transferase in surviving 3rd-instar *Aedes aegypti* larvae[1].
Cappariloside A (0-400 μg/mL; 72 h) inhibits the replication of influenza A virus strain A/PR/8/34 (H1N1) in MDCK cells, with an IC50 value of 115.25 μg/mL[2].
Cappariloside A (48 h) exhibits potent antiviral activity against human influenza virus subtypes A/PR/8/34 (H1N1), A/GZ/GIRD07/09 (H1N1 pdm2009) and A/HK/8/68 (H3N2) in MDCK cells, with IC50 values of 288.03, 362.18 and 375.73 μg/mL, and SI values of 4.36, 3.37 and 3.34, respectively[2].
Cappariloside A exhibits antiviral activity against PIV3 in LLC-MK2 cells (IC50 = 757.86 μg/mL, SI = 1.32), and against ADV3 in A549 cells (IC50 = 382.23 μg/mL, SI = 3.32)[2].
Cappariloside A (0-4 mg/mL; 6-72 h) inhibits the progeny replication of influenza A virus strain A/PR/8/34 (H1N1) in 16HBE cells, and suppresses virus-induced expression of IL-6, IP-10, MCP-1 and RANTES/CCL-5 at doses as low as 0.25 mg/mL[2].
Cappariloside A (0.25-2 mg/mL; 24, 48 h) inhibits the progeny replication of influenza A virus A/PR/8/34 (H1N1) in RAW264.7 cells, and suppresses the virus-induced expression of IP-10 and RANTES/CCL-5 at concentrations of 1 mg/mL and 0.5 mg/mL[2].
Cappariloside A (0-1 mg/mL; 24 h) inhibits the expression of IP-10 and RANTES/CCL-5 in 16HBE cells induced by avian influenza virus H9N2, but does not suppress viral replication[2].
Cappariloside A (0-2 mg/mL; 24 h) inhibits LPS (HY-D1056)-induced expression of IP-10, IL-6 and RANTES/CCL-5 in RAW264.7 cells without affecting TNF-α levels[2].
Cappariloside A (0-2 mg/mL; 6, 24, 48, 72 h) regulates the host IFN signaling pathway in 16HBE cells by inhibiting virus-induced STAT1 phosphorylation, reducing the expression of IFN-β and IL-29, and suppressing IFN-β-induced expression of IP-10 and RANTES/CCL-5[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cappariloside A Related Antibodies

ELISA Assay[2]

Cell Line: Human bronchial epithelial (16HBE) cells infected with avian influenza virus A/Chicken/Guangdong/1996 (H9N2)
Concentration: 1, 0.5, 0.25 mg/mL
Incubation Time: 24 h
Result: Significantly reduced H9N2-induced protein levels of IP-10 and RANTES/CCL-5 in a dose-dependent manner, despite no inhibition of H9N2 replication.

ELISA Assay[2]

Cell Line: Murine macrophage (RAW264.7) cells stimulated with lipopolysaccharide (LPS)
Concentration: 2, 1 mg/mL
Incubation Time: 24 h
Result: Significantly reduced LPS-induced protein levels of IP-10, IL-6, and RANTES/CCL-5 in a dose-dependent manner, with no effect on TNF-α levels.
In Vivo

Cappariloside A (75-300 mg/kg/day; oral administration; twice daily; for 5 consecutive days) dose-dependently inhibits influenza-induced inflammation and lung injury in female BALB/c mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 6-8 weeks old)[2]
Dosage: 75-300 mg/kg/day
Administration: p.o.; twice daily; 5 days
Result: Inhibited influenza-induced weight loss at day 3, 5, and 7 post-infection at 300 mg/kg·day; inhibited influenza-induced weight loss at day 3 post-infection at 150 and 75 mg/kg·day.
Reduced pulmonary index by 50% at day 5 post-infection at 300 mg/kg·day; reduced pulmonary index by 30% at day 5 post-infection at 150 mg/kg·day; reduced pulmonary index by 20% at day 5 post-infection at 75 mg/kg·day.
Inhibited total protein concentration increase in bronchoalveolar lavage fluid (BALF) at day 3, 5, and 7 post-infection at 300 mg/kg·day; inhibited total protein concentration increase in BALF at day 3, 5, and 7 post-infection at 150 mg/kg·day; inhibited total protein concentration increase in BALF at day 3 and 5 post-infection at 75 mg/kg·day.
Reduced inflammatory cell infiltration, inflammatory area, and pathology score in lung tissue at 300 mg/kg·day.
Decreased total white cell counts in BALF at day 5 post-infection at 300, 150, and 75 mg/kg·day.
Inhibited influenza-induced IL-6 and IP-10 levels in BALF at day 3, 5, and 7 post-infection at 300 mg/kg·day; inhibited influenza-induced IL-6 and IP-10 levels in BALF at day 3 and 5 post-infection at 150 and 75 mg/kg·day.
Molecular Weight

334.32

Formula

C16H18N2O6
CAS No.
SMILES

N#CCC1=CNC2=CC=CC(O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)=C21
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cappariloside A Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cappariloside A229483-41-4Glutathione S-transferaseInfluenza VirusInterleukin RelatedIFNARSTATGlutathione transferasesGSTsILInterferon-α/β receptorInterferon-alpha/beta receptorlarvicideAedes aegypti larvaeglutathione-S-transferaseinfluenza virusesBALB/c miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cappariloside A
Cat. No.:
HY-N17963
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.